Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.45 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.42 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.40 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.40 |
| ▸ | DPP4 | P27487 | 1/20 | 0.38 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32674587 | 0.86 | LMNA (0.51) | LMNATSHRMEN1CYP3A4KMT2A | |
| SCHEMBL21791552 | 0.86 | LMNA (0.51) | LMNATSHRMEN1CYP3A4KMT2A | |
| SCHEMBL2065376 | 0.86 | LMNA (0.51) | LMNATSHRMEN1CYP3A4KMT2A | |
| SCHEMBL21853751 | 0.86 | LMNA (0.51) | LMNATSHRMEN1CYP3A4KMT2A | |
| SCHEMBL4247092 | 0.86 | LMNA (0.51) | LMNATSHRMEN1CYP3A4KMT2A | |
| SCHEMBL9007595 | 0.86 | LMNA (0.51) | LMNATSHRMEN1CYP3A4KMT2A | |
| SCHEMBL21853762 | 0.86 | LMNA (0.51) | LMNATSHRMEN1CYP3A4KMT2A | |
| SCHEMBL4594968 | 0.85 | LMNA (0.50) | LMNATSHRMEN1CYP3A4KMT2A | |
| SCHEMBL4594965 | 0.85 | LMNA (0.47) | LMNATSHRMEN1CYP3A4KMT2A | |
| SCHEMBL2996166 | 0.82 | LMNA (0.48) | LMNATSHRMEN1CYP3A4KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160326157-A1 | MONOBACTAMS AND METHODS OF THEIR SYNTHESIS AND USE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2016-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160326157-A1 | MONOBACTAMS AND METHODS OF THEIR SYNTHESIS AND USE | MGAM, BPGM, MRPL21 | LMNA 928/4885TSHR 4614/4885MEN1 230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.